LNTH News and Press, Lantheus Holdings Inc. From 01/09/24

Option to license Perspective Therapeutics’ Pb212-VMT-α-NET asset Co-development rights for certain Pb212-based alpha therapies for prostate cancer Equity investment of up to 19.9% in Perspective Therapeutics Perspective Therapeutics intends to acquire Some...

BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Mary Anne Hei...

2024-01-01 12:52:26 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Undoubtedly, 2023 was the year of AI on Wall Street. We saw many AI-related companies absolutely skyrocket last year, with semiconductor firms leading the charge. Their meteoric rise and contin...

2023-12-26 07:43:47 ET More on POINT Biopharma Global Why POINT Biopharma Global Is At Least A Hold On Disappointing Readout POINT Biopharma Global: Why The Market Believes That A Second Bidder May Emerge Eli Lilly POINTs Toward Radiopharmaceutical Ambitions ...

2023-12-20 08:30:00 ET Summary Point Biopharma and Lantheus Holdings released positive topline results for their radioligand therapy in patients with metastatic castration-resistant prostate cancer. The SPLASH trial met its primary endpoint, showing a progression-free survival ben...

2023-12-19 14:14:12 ET More on Lantheus Lantheus: SPLASHdown, Navigating Waves In MCRPC Treatment Lantheus Holdings: Huge Catalysts Ahead And Cheap Valuation Lantheus Holdings, Inc. (LNTH) Q3 2023 Earnings Call Transcript Lantheus, Point BioPharma drop amid r...

2023-12-18 23:16:26 ET Summary Lantheus stock dropped 26% post-SPLASH study, highlighting risks in mCRPC drug development and its strategic alliance with POINT Biopharma. SPLASH trial met primary goals but showed underwhelming overall survival data, affecting investor confidence a...

2023-12-18 14:00:05 ET Summary Eli Lilly and Company wants to acquire POINT Biopharma Global Inc. with a tender offer of $12.5/share, which represented an 87% premium. POINT Biopharma Global is trading at $12.45, just $0.05 above the take-out price, and the tender offer could wrap...

2023-12-18 09:22:49 ET More on Lantheus, POINT Biopharma Global, etc. POINT Biopharma Global: Why The Market Believes That A Second Bidder May Emerge Lantheus Holdings: Huge Catalysts Ahead And Cheap Valuation Lantheus Holdings, Inc. (LNTH) Q3 2023 Earnings Call Tran...

2023-12-17 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...